Skip to main content
    E

    Eli Lilly and Company (LLY)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - GENERAL • NYSE

    $1433.55
    -9.95 (-0.69%)

    Market Cap: $1.29T

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Eli Lilly and Company (LLY) Financials: Revenue, Profit and Cash Flow

    Updated Oct 29, 2026. Financial statements from company filings, amounts in US dollars.

    Eli Lilly and Company reported revenue of $65.18B for the fiscal year ended Dec 31, 2025, up 44.7% from the year before. That year, net income was $20.64B with a net margin of 31.7%, operating cash flow was $16.81B and free cash flow was $8.97B. The quarter ended Sep 30, 2026 had revenue of $24.40B and net income of $6.45B.

    Revenue and Margins

    The operating margin was 40.4% in the fiscal year ended Dec 2025, the highest of the 10 years shown. Over the 9 years to Dec 2025, revenue grew from $21.22B, a compound annual rate of 13.3%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$65.18B+44.7%83.0%40.4%31.7%
    Dec 2024$45.04B+32.0%81.3%28.6%23.5%
    Dec 2023$34.12B+19.6%79.2%18.9%15.4%
    Dec 2022$28.54B+0.8%76.8%25.0%21.9%
    Dec 2021$28.32B+15.4%74.2%22.4%19.7%
    Dec 2020$24.54B+9.9%77.7%24.7%25.2%
    Dec 2019$22.32B+3.8%78.8%22.3%37.3%
    Dec 2018$21.49B+7.6%78.2%16.4%15.0%
    Dec 2017$19.97B-5.9%77.7%10.0%-1.0%
    Dec 2016$21.22BN/A73.1%15.4%12.9%
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, net income rose 94.9% from the year before. In the quarter ended Sep 2026, net income rose 15.6% from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Revenue$65.18B$45.04B$34.12B$28.54B$28.32B$24.54B$22.32B$21.49B$19.97B$21.22B
    Cost of revenue$11.05B$8.42B$7.08B$6.63B$7.31B$5.48B$4.72B$4.68B$4.45B$5.71B
    Gross profit$54.13B$36.63B$27.04B$21.91B$21.01B$19.06B$17.60B$16.81B$15.53B$15.51B
    Research and development$16.25B$14.27B$13.11B$8.10B$7.90B$6.75B$5.83B$7.04B$6.21B$5.34B
    Operating income$26.30B$12.90B$6.46B$7.13B$6.36B$6.06B$4.97B$3.53B$2.00B$3.26B
    Net income$20.64B$10.59B$5.24B$6.24B$5.58B$6.19B$8.32B$3.23B-$204.10M$2.74B
    EBITDA$27.73B$14.45B$8.08B$8.33B$7.70B$8.55B$6.50B$5.29B$3.87B$4.87B
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$24.40B$22.97B$19.80B$19.29B$17.60B$15.56B$12.73B$13.53B$11.44B$11.30B$8.77B$9.35B
    Gross profit$20.46B$19.71B$16.22B$15.92B$14.59B$13.11B$10.50B$11.13B$9.27B$9.13B$7.09B$7.57B
    Operating income$8.61B$8.98B$8.91B$8.37B$7.37B$6.87B$3.69B$5.15B$1.53B$3.71B$2.51B$2.39B
    Net income$6.45B$7.09B$7.40B$6.64B$5.58B$5.66B$2.76B$4.41B$970.30M$2.97B$2.24B$2.19B
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, total debt of $42.50B exceeded cash and equivalents by $35.23B.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets$112.48B$78.72B$64.01B$49.49B$48.81B$46.63B$39.29B$43.91B$44.98B$38.81B
    Current assets$55.63B$32.74B$25.73B$18.03B$18.45B$17.46B$13.71B$20.55B$19.20B$15.10B
    Cash and equivalents$7.27B$3.27B$2.82B$2.07B$3.82B$3.66B$2.34B$7.32B$6.54B$4.58B
    Total liabilities$85.94B$64.44B$53.14B$38.71B$39.65B$40.81B$36.59B$33.00B$33.31B$24.73B
    Short-term debt$1.64B$5.12B$6.90B$1.50B$1.54B$8.70M$1.50B$1.10B$3.71B$1.94B
    Long-term debt$40.87B$28.53B$18.32B$14.74B$15.35B$16.59B$13.82B$9.20B$9.94B$8.37B
    Shareholder equity$26.54B$14.27B$10.77B$10.65B$8.98B$5.64B$2.61B$9.83B$11.59B$14.01B
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$148.07B$142.28B$116.58B$112.48B$114.94B$100.92B$89.39B$78.71B$75.61B$71.87B$63.94B$64.01B
    Total liabilities$107.80B$108.40B$85.38B$85.94B$91.08B$82.57B$73.54B$64.44B$61.29B$58.24B$51.05B$53.14B
    Cash and equivalents$4.88B$8.95B$5.28B$7.16B$9.79B$3.38B$3.09B$3.27B$3.37B$3.22B$2.46B$2.82B
    Shareholder equity$40.27B$33.88B$31.20B$26.54B$23.79B$18.27B$15.76B$14.19B$14.24B$13.56B$12.81B$10.77B
    Last 12 quarters

    Cash Flow

    In the fiscal year ended Dec 2025, free cash flow was 53.4% of operating cash flow. Dividends and share repurchases together came to 105.8% of it.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow$16.81B$8.82B$4.24B$7.59B$7.37B$6.50B$4.84B$5.52B$5.62B$4.85B
    Capital expenditures$7.84B$5.06B$3.45B$1.85B$1.31B$1.39B$1.03B$1.21B$1.08B$1.04B
    Free cash flow$8.97B$3.76B$792.00M$5.73B$6.06B$5.11B$3.80B$4.31B$4.54B$3.81B
    Dividends paid$5.38B$4.68B$4.07B$3.54B$3.09B$2.69B$2.41B$2.31B$2.19B$2.16B
    Share repurchases$4.11B$2.50B$750.00M$1.50B$1.25B$500.00M$4.40B$4.15B$299.80M$600.10M
    Investing cash flow-$10.97B-$9.30B-$7.15B-$3.76B-$2.87B-$2.26B-$8.08B$1.91B-$3.78B-$3.14B
    Financing cash flow-$2.21B$1.23B$3.50B-$5.41B-$4.13B-$3.14B-$2.32B-$5.90B$142.60M-$559.80M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow$11.40B$10.69B$5.33B$3.22B$8.84B$3.09B$1.67B$2.47B$3.71B$1.47B$1.17B-$312.00M
    Capital expenditures$3.18B$2.93B$2.33B$2.55B$2.09B$1.70B$1.51B$1.50B$1.35B$1.22B$986.30M$1.07B
    Free cash flow$8.22B$7.76B$3.01B$677.90M$6.75B$1.39B$156.00M$977.70M$2.36B$241.40M$179.70M-$1.38B
    Last 12 quarters

    Frequently Asked Questions About LLY

    What is Eli Lilly and Company's annual revenue?

    Eli Lilly and Company reported revenue of $65.18B for the fiscal year ended Dec 31, 2025.

    How fast is Eli Lilly and Company's revenue growing?

    Revenue was up 44.7% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 31.7%.

    Is Eli Lilly and Company profitable?

    Yes. Eli Lilly and Company reported net income of $20.64B for the fiscal year ended Dec 31, 2025, with a net margin of 31.7%.

    How much free cash flow does LLY generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of $16.81B minus capital expenditures of $7.84B produced free cash flow of $8.97B.

    How much debt does Eli Lilly and Company have?

    The balance sheet dated Dec 31, 2025 reported long-term debt of $40.87B, short-term debt of $1.64B and cash and equivalents of $7.27B.